Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15616MR)

This product GTTS-WQ15616MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF13C gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_052945.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 115650
UniProt ID Q96RJ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15616MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15460MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ2524MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ6830MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ4216MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ3713MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ824MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ15716MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ15199MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW